CDTX Similar Chart Price Prediction
The price of CDTX is predicted to go up -4.32%, based on the high correlation periods with E. The similarity of these two price pattern on the periods is 95.27%.
CDTX
E
Down: -4.32%Similarity: 95.27%
CDTX Revenue Forecast
CDTX EPS Forecast
CDTX Analyst's Forecast
Gregory Renza
RBC Capital
Buy
2024-12-13
Price Target
$34
Upside
+51.11%
RBC Capital analyst Gregory Renza initiated coverage of Cidara Therapeutics with an Outperform rating and $34 price target. The firm sees the commercial potential for CD388, an innovative therapeutic class based on Cidara's Cloudbreak platform. The unique mechanism of action of CD388 could provide universal protection against broad influenza viruses and throughout the flu season, the analyst tells investors in a research note. RBC believes "there is currently room" for new flu prevention innovations, and its projections estimate that CD388 could achieve global peak revenues of $1.1B by 2033.
Seamus Fernandez
Guggenheim
Strong Buy
2024-11-08
Price Target
$33
Upside
+144.44%
